Kevin Scanlon, Ph.D.
| Berlex Biosciences | # of Grants: 1 |
Grants
| H-Ras Ribozyme Mediated Tumor Suppression of BUX Cells | 1995 (Cycle 4) | $352,183 |
| Cancer | Research Project Awards | |
Publications
| Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme | ||||
| Periodical: Cancer Research | Index Medicus: | |||
| Authors: Feng M, Cabrera G, Scanlon K, Curiel D | ART | |||
| Yr: 1995 | Vol: 55 | Nbr: 10 | Abs: | Pg: 2024-2028 |
| Oligonucleotide-mediated modulation of mammalian gene expression | ||||
| Periodical: FASEB Journal | Index Medicus: | |||
| Authors: Scanlon KJ, Ohta Y, Ishida H, et al | ART | |||
| Yr: 1995 | Vol: 9 | Nbr: | Abs: | Pg: 1288-1296 |
| Therapeutic applications of ribozymes | ||||
| Periodical: Pharmacology and Therapeutics | Index Medicus: | |||
| Authors: Kijima H, Ishida H, Ohkawa T, Kashani-Sabet M, Scanlon KJ | ART | |||
| Yr: 1995 | Vol: 68 | Nbr: 2 | Abs: | Pg: 247-267 |
| Application of ribozymes to cancer gene therapy | ||||
| Periodical: Cancer Gene Therapy | Index Medicus: | |||
| Authors: Kashani-Sabet M, Scanlon KJ | ART | |||
| Yr: 1995 | Vol: 2 | Nbr: 3 | Abs: | Pg: 213-223 |
| Suppression of the malignant phenotype of melanoma cells by anti-oncogene ribozymes | ||||
| Periodical: Journal of Investigative Dermatology | Index Medicus: | |||
| Authors: Ohta Y, Kijima H, Kashani-Sabet M, Scanlon KJ | ART | |||
| Yr: 1996 | Vol: 106 | Nbr: 2 | Abs: | Pg: 1-6 |
| Tissue-specific expression of an anti-ras ribozyme inhibits proliferation of human malignant melanoma cells | ||||
| Periodical: Nucleic Acids Research | Index Medicus: | |||
| Authors: Ohta Y, Kijima H, Kashani-Sabet, Scanlon KJ | ART | |||
| Yr: 1996 | Vol: 24 | Nbr: 5 | Abs: | Pg: |
| Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme | ||||
| Periodical: Cancer Research | Index Medicus: | |||
| Authors: Feng M, Cabrera G, Scanlon K, Curiel D | ART | |||
| Yr: 1995 | Vol: 55 | Nbr: 10 | Abs: | Pg: 2024-2028 |
| Oligonucleotide-mediated modulation of mammalian gene expression | ||||
| Periodical: FASEB Journal | Index Medicus: | |||
| Authors: Scanlon KJ, Ohta Y, Ishida H, et al | ART | |||
| Yr: 1995 | Vol: 9 | Nbr: | Abs: | Pg: 1288-1296 |
| Therapeutic applications of ribozymes | ||||
| Periodical: Pharmacology and Therapeutics | Index Medicus: | |||
| Authors: Kijima H, Ishida H, Ohkawa T, Kashani-Sabet M, Scanlon KJ | ART | |||
| Yr: 1995 | Vol: 68 | Nbr: 2 | Abs: | Pg: 247-267 |
| Application of ribozymes to cancer gene therapy | ||||
| Periodical: Cancer Gene Therapy | Index Medicus: | |||
| Authors: Kashani-Sabet M, Scanlon KJ | ART | |||
| Yr: 1995 | Vol: 2 | Nbr: 3 | Abs: | Pg: 213-223 |
| Suppression of the malignant phenotype of melanoma cells by anti-oncogene ribozymes | ||||
| Periodical: Journal of Investigative Dermatology | Index Medicus: | |||
| Authors: Ohta Y, Kijima H, Kashani-Sabet M, Scanlon KJ | ART | |||
| Yr: 1996 | Vol: 106 | Nbr: 2 | Abs: | Pg: 1-6 |
| Tissue-specific expression of an anti-ras ribozyme inhibits proliferation of human malignant melanoma cells | ||||
| Periodical: Nucleic Acids Research | Index Medicus: | |||
| Authors: Ohta Y, Kijima H, Kashani-Sabet, Scanlon KJ | ART | |||
| Yr: 1996 | Vol: 24 | Nbr: 5 | Abs: | Pg: |